Cargando…
Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness
Neisseria gonorrhoeae bacteria are acknowledged as an urgent threat to human health because this species has developed resistances to all of the antibiotics used clinically to treat its infections. N. gonorrhoeae causes the sexually transmitted disease gonorrhoea, but also causes blindness when the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374094/ https://www.ncbi.nlm.nih.gov/pubmed/32694582 http://dx.doi.org/10.1038/s41598-020-68722-8 |
_version_ | 1783561621965111296 |
---|---|
author | Churchward, Colin P. Al-Kinani, Ali A. Abdelkader, Hamdy Swinden, Julian Siwoku, Opeoluwa Varnakulasingam, Thinuba Alany, Raid G. Snyder, Lori A. S. |
author_facet | Churchward, Colin P. Al-Kinani, Ali A. Abdelkader, Hamdy Swinden, Julian Siwoku, Opeoluwa Varnakulasingam, Thinuba Alany, Raid G. Snyder, Lori A. S. |
author_sort | Churchward, Colin P. |
collection | PubMed |
description | Neisseria gonorrhoeae bacteria are acknowledged as an urgent threat to human health because this species has developed resistances to all of the antibiotics used clinically to treat its infections. N. gonorrhoeae causes the sexually transmitted disease gonorrhoea, but also causes blindness when the bacteria infect the eyes. Infants are particularly susceptible, acquiring the infection from their mothers at birth. We have shown that the monoglyceride monocaprin rapidly kills N. gonorrhoeae and other bacterial species and is non-irritating in ocular assays. Here we show that the physical and chemical properties of monocaprin make it ideal for use in a thickened eye drop formulation to combat eye infections. Monocaprin-containing formulations were assessed using analytical techniques and for antimicrobial activity in vitro and in ex vivo infections. Monocaprin-containing formulations retained activity after three years and are non-irritating, unlike preparations of povidone iodine in our assays. A recommended formulation for further development and investigation is 0.25% monocaprin in 1% HPMC with 1% polysorbate 20. |
format | Online Article Text |
id | pubmed-7374094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73740942020-07-22 Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness Churchward, Colin P. Al-Kinani, Ali A. Abdelkader, Hamdy Swinden, Julian Siwoku, Opeoluwa Varnakulasingam, Thinuba Alany, Raid G. Snyder, Lori A. S. Sci Rep Article Neisseria gonorrhoeae bacteria are acknowledged as an urgent threat to human health because this species has developed resistances to all of the antibiotics used clinically to treat its infections. N. gonorrhoeae causes the sexually transmitted disease gonorrhoea, but also causes blindness when the bacteria infect the eyes. Infants are particularly susceptible, acquiring the infection from their mothers at birth. We have shown that the monoglyceride monocaprin rapidly kills N. gonorrhoeae and other bacterial species and is non-irritating in ocular assays. Here we show that the physical and chemical properties of monocaprin make it ideal for use in a thickened eye drop formulation to combat eye infections. Monocaprin-containing formulations were assessed using analytical techniques and for antimicrobial activity in vitro and in ex vivo infections. Monocaprin-containing formulations retained activity after three years and are non-irritating, unlike preparations of povidone iodine in our assays. A recommended formulation for further development and investigation is 0.25% monocaprin in 1% HPMC with 1% polysorbate 20. Nature Publishing Group UK 2020-07-21 /pmc/articles/PMC7374094/ /pubmed/32694582 http://dx.doi.org/10.1038/s41598-020-68722-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Churchward, Colin P. Al-Kinani, Ali A. Abdelkader, Hamdy Swinden, Julian Siwoku, Opeoluwa Varnakulasingam, Thinuba Alany, Raid G. Snyder, Lori A. S. Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness |
title | Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness |
title_full | Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness |
title_fullStr | Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness |
title_full_unstemmed | Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness |
title_short | Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness |
title_sort | monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374094/ https://www.ncbi.nlm.nih.gov/pubmed/32694582 http://dx.doi.org/10.1038/s41598-020-68722-8 |
work_keys_str_mv | AT churchwardcolinp monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT alkinanialia monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT abdelkaderhamdy monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT swindenjulian monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT siwokuopeoluwa monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT varnakulasingamthinuba monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT alanyraidg monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT snyderlorias monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness |